{"id":2452,"date":"2020-11-10T08:42:12","date_gmt":"2020-11-10T07:42:12","guid":{"rendered":"https:\/\/cendoc.h12o.es\/blog\/?p=2452"},"modified":"2020-11-10T08:42:12","modified_gmt":"2020-11-10T07:42:12","slug":"mieloma-multiple-covid-19-y-h12o-2","status":"publish","type":"post","link":"https:\/\/cendoc.h12o.es\/blog\/2020\/11\/10\/mieloma-multiple-covid-19-y-h12o-2\/","title":{"rendered":"Mieloma m\u00faltiple, COVID-19 y H12O (2)"},"content":{"rendered":"<p data-adtags-visited=\"true\">Una infecci\u00f3n es la principal causa de morbilidad y mortalidad en pacientes con mieloma m\u00faltiple. De ah\u00ed la necesidad de realizar estudios sobre el impacto de la COVID-19 en este grupo de pacientes. Joaqu\u00edn Mart\u00ednez L\u00f3pez, del Servicio de Hematolog\u00eda del Hospital 12 de Octubre, ha participado en un estudio retrospectivo internacional donde se describen las caracter\u00edsticas y resultados de 650 pacientes con mieloma m\u00faltiple,\u00a0 a partir de los datos recogidos por la Sociedad Internacional de Mieloma<img loading=\"lazy\" decoding=\"async\" class=\" wp-image-3871 alignright\" src=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg\" alt=\"logo12\" width=\"243\" height=\"165\" data-attachment-id=\"3871\" data-permalink=\"https:\/\/coronavirusbiblioh12o.wordpress.com\/2020\/05\/06\/7-mas-del-h12o\/logo12\/\" data-orig-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg\" data-orig-size=\"275,183\" data-comments-opened=\"1\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;}\" data-image-title=\"logo12\" data-image-description=\"\" data-medium-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" data-large-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" \/>.<\/p>\n<p data-adtags-visited=\"true\">El trabajo, bajo el t\u00edtulo \u201c<a href=\"https:\/\/ashpublications.org\/blood\/article\/doi\/10.1182\/blood.2020008150\/474113\/Clinical-Features-Associated-with-COVID-19-Outcome\" target=\"_blank\" rel=\"noopener noreferrer\">Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset<\/a>\u201d, ha sido publicado a primeros de noviembre en la revista <em>Blood<\/em>. La mediana de edad de los pacientes era de 69 a\u00f1os, la mitad eran tratados con terapias de primera l\u00ednea, un tercio hab\u00eda sido diagnosticado de mieloma hace 1 o 2 a\u00f1os,\u00a0 y tambi\u00e9n un tercio falleci\u00f3 por COVID-19. El an\u00e1lisis multivariante encontr\u00f3 que la edad, el mieloma de alto riesgo y la enfermedad renal eran predictores independientes de resultados adversos. Los autores concluyen que el tratamiento del mieloma m\u00faltiple en tiempos de la COVID-19 requiere de un an\u00e1lisis cuidadoso de los factores relacionados con la enfermedad para disminuir el riesgo de contraer esta infecci\u00f3n y realizan una serie de recomendaciones para el manejo de este grupo de pacientes.<\/p>\n<p data-adtags-visited=\"true\">Equipo Biblioteca H12O<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Una infecci\u00f3n es la principal causa de morbilidad y mortalidad en pacientes con mieloma m\u00faltiple. De ah\u00ed la necesidad de realizar estudios sobre el impacto de la COVID-19 en este grupo de pacientes. Joaqu\u00edn Mart\u00ednez L\u00f3pez, del Servicio de Hematolog\u00eda del Hospital 12 de Octubre, ha participado en un estudio \u2026<\/p>\n<p class=\"continue-reading-button\"> <a class=\"continue-reading-link\" href=\"https:\/\/cendoc.h12o.es\/blog\/2020\/11\/10\/mieloma-multiple-covid-19-y-h12o-2\/\">Continuar leyendo<i class=\"crycon-right-dir\"><\/i><\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false},"version":2}},"categories":[4,64,46],"tags":[],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p3G9TJ-Dy","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/2452"}],"collection":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/comments?post=2452"}],"version-history":[{"count":1,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/2452\/revisions"}],"predecessor-version":[{"id":2453,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/2452\/revisions\/2453"}],"wp:attachment":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/media?parent=2452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/categories?post=2452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/tags?post=2452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}